Targeting CD39-Adenosine Pathway for Immuno-Oncology
Time: 8:30 am
day: Day Two
Details:
- Why CD39 is an excellent target for cancer immune-oncology
- Preclinical characterization of eurestobart (ES002), Elpiscience’s anti-CD39 antibody
- Effect of ES014, a first-in-class bi-specific antibody targeting CD39 and TGF-beta, in modulating the immune system in the tumor microenvironment (TME)
